Table 2

Adverse Events in ≥ 20% of Study Population

Adverse Event, n (%)

MF-DPI

200 μg QD AM

(n = 78)

MF-DPI

100 μg BID

(n = 74)

BDP

168 μg BID

(n = 81)

Allergy

22 (28)

11 (15)

20 (25)

Fever

18 (23)

20 (27)

26 (32)

Headache

33 (42)

27 (36)

25 (31)

Viral infection

27 (35)

26 (35)

29 (36)

Nasal congestion

7 (9)

17 (23)

11 (14)

Pharyngitis

26 (33)

25 (34)

25 (31)

Rhinitis

29 (37)

20 (27)

22 (27)

Sinusitis

15 (19)

15 (20)

11 (14)

Upper respiratory tract infection

38 (49)

35 (47)

41 (51)

BID = twice daily; BDP = beclomethasone dipropionate; MF-DPI = mometasone furoate administered via a dry powder inhaler; QD AM = once daily in the morning.

Noonan et al. BMC Pediatrics 2009 9:43   doi:10.1186/1471-2431-9-43